REVIAN® RED System, Among the Best Hair-Loss Treatments According to Doctors

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

Immunocore to present at the Jefferies London Healthcare Conference

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Mycovia Pharmaceuticals Announces Completion of Partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 Clinical Study Evaluating Oteseconazole for Treatment of Acute Vulvovaginal Candidiasis (VVC) in China

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

EmitBio™ Granted Biotech Patent Covering Light to Treat COVID-19 and other Diseases

Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

Poseida Therapeutics Announces Leadership Appointments

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting

Mycovia Pharmaceuticals Announces Presentations of its Supportive Phase 3 Clinical Study (ultraVIOLET) Evaluating the Safety and Efficacy of Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) and Susceptibility Testing Against Clinical Isolates at IDWeek 2021 Virtual Conference

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

Immunocore to present at upcoming investor conferences

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

EmitBio Results Yield 99.99% Reduction of Delta in Human Tissue

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

Mycovia Pharmaceuticals Announces Presentation of Oteseconazole (VT-1161) Phase 3 Data Demonstrating Safety and Efficacy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) at the 2021 IDSOG Annual Meeting

Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Immunocore to present at upcoming investor conferences

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

Immunocore Reports First Quarter 2021 Financial Results

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research 2021 Annual Meeting

EmitBio Treatment Broadly Effective Against Coronavirus Variants

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

EmitBio Demonstrates Statistically Significant Results in Clinical Trial for COVID-19 Treatment

Immunocore announces key appointments to management and Board

Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement

Immunocore Announces Pricing of Upsized Initial Public Offering

EmitBio Demonstrates New Treatment is Effective Against Multiple Types of Coronavirus

EmitBio Announces Positive Clinical Results Supporting A Novel Therapeutic for COVID-19

Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)

Immunocore announces closing of $75.0 Million Series C round

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

Mycovia Pharmaceuticals Announces Positive Topline Results from its Third Phase 3 Clinical Trial (ultraVIOLET) of Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event

Poseida Therapeutics Added to NASDAQ Biotechnology Index

Poseida Therapeutics Appoints Luke Corning to Board of Directors

Mycovia Pharmaceuticals Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis

Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Phase 3 “ultraVIOLET Study” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma

Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020

Mycovia Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 “VIOLET Studies” for Oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC)

Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19

Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director

Wren Therapeutics Announces Publication in Nature Research Journal

Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index

Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020

KNOW Bio Announces Breakthrough Nitric Oxide Discovery to Combat COVID-19

Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B

Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole for the Treatment of Acute Vulvovaginal Candidiasis

Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020

Poseida Form 8-K P-PSMA-101 Update

Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis

Mycovia Pharmaceuticals CEO Patrick Jordan Named 2020 Life Sciences CEO of the Year by Triangle Business Journal

Poseida Therapeutics appoints Harry J. Leonhardt, Esq. as General Counsel

Poseida Therapeutics Announces Pricing of Initial Public Offering

Poseida Therapeutics Raises $110 Million in Series D Financing

Kymab Wins Supreme Court Case Against Regeneron

Mycovia Pharmaceuticals to Participate in On-Demand Women’s Health Panel at BIO Digital 2020

Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents

Immunocore announces dosing of first patient with fourth ImmTAC®

Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer

KNOW Bio – REVIAN RED Wins 2020 MedTech Breakthrough Award for Best New Dermatology Solution

Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy

Xenex LightStrike Robot Destroys SARS-CoV-2 (Coronavirus) in 2 Minutes; First & Only UV Disinfection Technology Proven to Deactivate COVID-19 Virus

Mycovia Pharmaceuticals Expands Medical Affairs Team with Strategic New Hire

Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron

Altan Pharmaceuticals announces the launch of Tobramycin in Spain

Immunocore – First Site in Global Uveal Melanoma Patient Registry Now Open

Immunocore Secures $130 Million Series B Financing

Altan Pharmaceuticals introduces the generic formulation of Dexmedetomidine

Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

Novan Provides SB206 Program and Business Update

KNOW Bio – REVIAN® Presents Leading Clinical Trial Results for New Hair Loss Treatment

Mycovia Pharmaceuticals Expands Commercialization Team with Strategic New Hires

KNOW Bio – REVIAN® Inc. Announces Issuance of Landmark Patent Covering the Use of Light to Stimulate the Body to Heal Itself

Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum

KNOW Bio Announces Acquisition of Clinical Sensors, Inc.

Novan Announces Planned Chief Executive Officer Transition

Mycovia Pharmaceuticals Completes Enrollment in its Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

Immunocore announces dosing of first patient with third ImmTAC® bispecific

Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition

KNOW Bio – REVIAN® Names President to Commercialize Medical Grade LED Light Therapy for Hair Growth

Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019

Mycovia Pharmaceuticals Announces Early Completion of Enrollment for Global Phase 3 Clinical Trials for VT-1161 (VIOLET) for the Treatment of Recurrent Vulvovaginal Candidiasis

Immunocore – New Data Uncover Deeper Insight into Tebentafusp (IMCgp100) Clinical Activity in Patients with Advanced Melanoma, Including Uveal

Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting

Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting

Immunocore to Spotlight ImmTAC® Platform Research at 2019 SITC Annual Conference

KNOW Bio – Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model

Mycovia Pharmaceuticals to Present at 2019 BIO Investor Forum

Novan Further Expands its Proprietary Nitric Oxide Platform

Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Candidiasis

Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer

KNOW Bio – Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11

Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis

Kymab Outlines Positive New Findings for its KY1044 AntiICOS Program at the CICON 2019 Annual Meeting

Novan Awarded Approximately $1.1 Million Grant by Department of Defense

Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Novan Hires Michelle Patterson as Vice President of Project Management

Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

Kymab has defeated an opposition by Regeneron against the grant of an Australian patent covering transgenic mouse platforms for antibody discovery on all grounds

Novan Advances Women’s Health Business Unit with Non-Dilutive Funding

Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment

Novan Takes Steps to Reduce Real Estate Footprint

Mycovia Appoints Tiffany Ahlers as Senior Vice President, Commercialization

Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production

Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma

Immunocore: Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers

Kymab Appoints Catherine Moukheibir as Non-Executive Director

Novan SB206 Phase 3 Molluscum Pivotal Program Update

Xenex: LightStrike Robot Proven Effective at Destroying Deadly Superbug Candida Auris in New Published Study

Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies

Novan Expands External Business Partner Network

Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Announce Partnership to Develop and Commercialize VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions

Kymab Announces Presentations at the 24th EHA Annual Congress

Novan to Participate in JMP Securities Life Sciences Conference

Artizan Biosciences Announces Corporate Progress and Financing

Novan Achieves Compliance with Nasdaq Listing Rule 5450(b)(2)(A)

First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program

Immunocore – New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma

Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting

Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019

Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York

Kymab Announces Abstracts to be Presented at the 24th EHA Annual Congress

Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting

KNOW Bio Announces Closing of $30 Million in Equity Financing

Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer

Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma

Kymab Rule 135 Press Release

Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting

Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer

Novan Completes Funding Transaction with Ligand Pharmaceuticals

Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019

Novan Confirms Corporate Update Conference Call and Webcast

Novan Secures Up to $35 Million in Non-Dilutive Funding

Poseida Therapeutics Raises $142 Million in Series C Financing

Study Published in Antimicrobial Agents and Chemotherapy Finds Antifungal Compound VT-1598 Developed by Mycovia Pharmaceuticals Demonstrates In Vitro and In Vivo Activity Against Deadly Candida Auris Fungus

Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer

Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma

Novan and Sato Advance Japan Market and Dermatology Partnership

Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates

Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis

Mayo Clinic Study Reports 47% Reduction in C.diff Infection Rates Using Pulsed Xenon UV Room Disinfection

Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

Altan Pharma Submits New Drug Application for Acetaminophen Solution for Infusion for Treatment of Pain and Reduction of Fever

Melinta Therapeutics Provides Corporate Updates

Novan Provides Business Update

Wren Therapeutics completes £18 million Series A financing

Immunocore names David Berman as Head of R&D

Immunocore appoints Bahija Jallal as Chief Executive Officer

Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions

Novan Announces Management Changes and Provides Business Update

Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million ~

John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics

Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit

Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Kymab granted leave to appeal to the UK Supreme Court

Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting

Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)

Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech

Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results

Novan Announces Corporate Update Conference Call and Webcast

Melinta Therapeutics Reports Third Quarter 2018 Financial Results

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101

Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors

Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP

Novan Creates Dedicated Women’s Health Business Unit

Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer

Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan

Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program

Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries

Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November

Novan Receives FDA Guidance for SB204 and Acne Indication

Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)

Melinta Therapeutics Names Peter Milligan as Chief Financial Officer

Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis

Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Immunocore strengthens IP position in the field of TCR-based therapeutics

Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018

Novan Announces Promising Clinical Results with SB414

Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract

Melinta Therapeutics Reports Second Quarter 2018 Financial Results

Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies

Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases

Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

Poseida Therapeutics Appoints John P. Schmid to Board of Directors

Immunocore Management Change

New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma

Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Melinta Therapeutics Announces Pricing of Public Offering of Common Stock

Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting

Melinta Therapeutics Announces Proposed Offering of Common Stock

SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

Novan Provides Update on SB414 Inflammatory Skin Disease Development Program

Melinta Therapeutics Reports First Quarter 2018 Financial Results

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA

Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations

Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

Altan Pharma Announces the Grant of Two Patents by the USPTO

Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018

Novan Advances Organization and Strengthens Leadership Team

Poseida Raises $30.5 Million in Series B Financing

Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe

Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference

Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer

Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018

Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ in Patients with cUTI

Dr. Eugene Sun Appointed to Novan Board of Directors

Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne

Immunocore Announces Leadership Change

Novoclem announces CEO Anne Whitaker to present at the BIO CEO & Investor Annual Conference on Monday February 12th, 2018

Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations

Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States

Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206

Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

Xenex LightStrike Germ-Zapping Robots Helping Stanford Health Care – ValleyCare Destroy Germs and Bacteria

Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio

Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants

Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on Wednesday, January 10, 2018

Novan Announces Proposed Public Offering of Common Stock and Warrants

Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors

Novoclem announces issuance of patent covering a core technology underlying its Cystic Fibrosis therapeutic development program

NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program